ライフサイエンスコーパス: bone cancer

1 typical of the changes and heterogeneity in bone cancer.

2 s NGF blockade might confer in patients with bone cancer.

3 ith lipopolysaccharide (LPS) or in mice with bone cancer.

4 aracterized by bone dysplasia, myopathy, and bone cancer.

5 eed of dogs that exhibit a high incidence of bone cancer.

6 ow support was conducted to treat metastatic bone cancer.

7 ks behaviors indicative of pain in mice with bone cancer.

8 ar to that found in patients with osteolytic bone cancer.

9 ted dorsal root ganglia in a murine model of bone cancer.

10 ypes, and is present in approximately 25% of bone cancers.

11 tion as a cell-based gene delivery system to bone cancers.

12 ght to drive a subset of pediatric brain and bone cancers.

13 ficant clinical utility in the management of bone cancer and bone cancer pain.

14 mor that constitutes approximately 6% of all bone cancers and is the most frequently occurring adult

15 l SCs combined and for soft tissue sarcomas, bone cancers, and melanoma were calculated.

16 F-353 administration onto the spinal cord of bone cancer animals.

17 g pain, and effective therapies for treating bone cancer are lacking.

18 Primary and metastatic bone cancers are difficult to eradicate and novel approa

19 siRNA can effectively treat pain induced by bone cancer by blocking the AKT-ERK signaling pathway.

20 Whereas pain resulting from bone cancer can dramatically impact an individual's qual

21 Nerve injury and bone cancer caused a rapid-onset and long-lasting expres

22 signaling in normal bone development and in bone cancer could potentially lead to therapies modulati

23 As bone cancer grows, osteoclasts, the principal bone-resor

24 Osteosarcoma is a highly metastatic form of bone cancer in adolescents and young adults that is resi

25 Osteosarcoma is the most common bone cancer in children and adolescents.

26 Ewing sarcoma is the second-most-common bone cancer in children.

27 Osteosarcoma (OS), the most common primary bone cancer in dogs, is commonly treated with adjuvant d

28 ropathic pain after sciatic nerve injury and bone cancer in rodents.

29 s in the diagnosis and therapy of metastatic bone cancer, in which radioactive metal ions including (

30 We demonstrated previously that rats with bone cancer learn to prefer a context paired with saphen

31 tment of chronic pain states associated with bone cancer metastasis.

32 helpful information in a rat mammary-derived bone cancer model.

33 Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be i

34 um subarachnoidale of animals suffering from bone cancer pain and animals in the negative group.

35 and suggest a potential target for treating bone cancer pain and improving analgesic effect of morph

36 pinal cord is critical to the development of bone cancer pain and morphine tolerance in treating bone

37 cal mechanism underlying the pathogenesis of bone cancer pain and suggest a potential target for trea

38 destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an

39 This "neurochemical signature" of bone cancer pain appears unique when compared to changes

40 cking reagent EphB2-Fc prevents and reverses bone cancer pain behaviors and the associated induction

41 ighly significant prevention and reversal of bone cancer pain behaviour.

42 Treating bone cancer pain continues to be a clinical challenge an

43 nduced by the development of neuropathic and bone cancer pain in animal models.

44 used to attenuate nociception in a model of bone cancer pain in mice.

45 vity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced

46 ptor reverses morphine tolerance in treating bone cancer pain in rats and defensive pain in mice.

47 Bone cancer pain is a major clinical problem and remains

48 Bone cancer pain is common among cancer patients and can

49 cer pain arises from metastases to bone, and bone cancer pain is one of the most difficult of all per

50 chief problem in designing new therapies for bone cancer pain is that it is unclear what mechanisms d

51 Bone cancer pain most commonly occurs when tumors origin

52 nical challenge and underlying mechanisms of bone cancer pain remain elusive.

53 Data generated in a murine model of bone cancer pain suggest that a disturbance of local end

54 sibility that it is an important mediator of bone cancer pain via its capacity to detect osteoclast-

55 The rat model of bone cancer pain was induced by implanting rat mammary g

56 mouse femur and that, in an in vivo model of bone cancer pain, acute or chronic administration of a T

57 Using a well-established rat model of bone cancer pain, AF-353, a recently described potent an

58 uced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical

59 ical hyperalgesia developed in the rats with bone cancer pain, and these effects were accompanied by

60 ne the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media

61 in to define the role COX-2 plays in driving bone cancer pain, we used an in vivo model where murine

62 attenuated both ongoing and movement-evoked bone cancer pain, whereas chronic inhibition of COX-2 si

63 icant reduction in both early and late stage bone cancer pain-related behaviors that was greater than

64 on, mice develop ongoing and movement-evoked bone cancer pain-related behaviors, extensive tumor-indu

65 echanical hypersensitivity in a rat model of bone cancer pain.

66 ssion level in the spinal cord is reduced in bone cancer pain.

67 educes pain hypersensitivity associated with bone cancer pain.

68 ach for treating neuropathic pain, including bone cancer pain.

69 mal and mechanical hyperalgesia in rats with bone cancer pain.

70 ncer pain and morphine tolerance in treating bone cancer pain.

71 tributes to analgesic efficacy in a model of bone cancer pain.

72 fer a promising therapeutic tool in treating bone cancer pain.

73 s a promising strategy for the management of bone cancer pain.

74 life in patients with prostate tumor-induced bone cancer pain.

75 d growth factor (PDGF) was used to alleviate bone cancer pain.

76 utility in the management of bone cancer and bone cancer pain.

77 whether ATP and P2X3 receptors contribute to bone-cancer pain in a mouse model, immunohistochemical t

78 avity tumor cell implantation (TCI) produces bone cancer-related thermal hyperalgesia, mechanical all

79 TGF)-beta1, a crucial molecule in metastatic bone cancer, stimulates collagenase-3 expression in the

80 Chordoma is a rare bone cancer that is aggressive, locally invasive, and ha

81 ility of fDM as a biomarker for detection of bone cancer treatment efficacy, thus warranting clinical

82 body was administered in a prostate model of bone cancer where significant bone formation and bone de

83 e for the palliation of pain from metastatic bone cancer, whereas rhenium-186 and rhenium-188 are inv

84 killing in vivo revealed dramatic killing of bone cancer with only a modest effect on osteoclast numb